Akumina Named A Strong Performer in 2020 Intranet Platforms Evaluation by Leading Independent Research Firm
16.6.2020 18:47:00 EEST | Business Wire | Press release
Akumina, the leading global Employee Experience Platform (EXP) software provider and one of INC Magazine’s Top 200 fastest growing companies in North America, announced today that they’ve been named a Strong Performer by Forrester Research, Inc. in The Forrester Wave™: Intranet Platforms, Q2 2020 report.
Akumina received the highest scores possible in seven criteria, including Personalization, Integration & Interoperability, and Design Tools.
Akumina’s inclusion in this evaluation is important especially to large enterprises working to improve employee experience, as it shows the strength and innovation of the organization’s technology. Many large enterprise customers like Banner Health, ING, and GlaxoSmithKline have already successfully partnered with Akumina.
“The Forrester Wave report is a well-respected resource for global organizations looking to partner with a software vendor ranked favorably in product quality, overall strategy, industry expertise and proven customer success,” says Akumina President and Co-Founder, David Maffei. “We feel being named a Strong Performer in the Forrester Wave reinforces our belief in the power of our platform and our strategy. It’s humbling and exciting to earn such a high honor from a respected independent third party like Forrester.”
Customer perspective is also considered an important part of the evaluation, which states, “Reference customers attest to the power of Akumina’s design tools, ease of content creation/editing, and ability to personalize communication.”
Akumina is laser focused on transforming the employee experience for medium and large enterprises around the globe with north of 4.5 million daily active users and customers using the platform in 80 countries and in over 60 different languages.
“Our intranet has become a unified, personalized platform connecting our employees to tools, information and each other. It empowers employees to take action, find solutions and share knowledge and experiences,” says Keith Kratochvil, Enterprise Architect at long-time Akumina customer the Principal Financial Group.
Akumina has also received recognition from organizations like ClearBox Consulting, The Tech Tribune, and CIO Review and has partnered with industry leaders such as Avanade, the leading digital innovator in the Microsoft ecosystem.
“Avanade is extremely excited with Akumina’s inclusion and placement in the 2020 Forrester Wave Report for Intranet Platforms. We took a strategic position in Akumina to help our clients to drive adoption and effective use of Digital Workplace tools at enterprise scale and we’ve seen our enterprise clients achieve strong results pivoting to a Digital-Hub-on-Akumina approach to reduce day-to-day friction in their organizations,” said Florin Rotar, Executive, Global Modern Workplace Lead at Avanade & Accenture Microsoft Business Group.
To learn more about Akumina, or to download a copy of the Forrester Wave™ Report on Intranet Platforms, please visit www.akumina.com.
About Akumina
Akumina is the employee experience platform that empowers global enterprises to quickly create personalized digital experiences that help every employee in every role work smarter, not harder. By offering a customizable, brandable and multilingual platform that seamlessly integrates with leading enterprise cloud applications, Akumina delivers a contextual, collaborative, and engaging workplace experience to every user on any device. Akumina’s customers include ING, Principal Financial Group, Whole Foods Market, GlaxoSmithKline, Vodafone, the Boston Red Sox and the Department of Defense. To learn more visit www.akumina.com or follow us on LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005822/en/
Contact information
Michael Scott
VP of Marketing
Michael.Scott@akumina.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom